Company Filing History:

15 out of 525

Ludwig Institute for Cancer Research Limited

patents

3 out of 1,744

Institut National De La Sante Et De La Recherche Medicale

University of California

patents

where one patent can have more than one assignee

Years Active: 1996-2003

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6669946 - METHOD FOR IDENTIFYING INDIVIDUALS SUFFERING FROM A CELLULAR ABNORMALITY SOME OF WHOSE ABNORMAL CELLS PRESENT COMPLEXES OF HUMAN LEUKOCYTE ANTIGEN TYROSINASE DERIVED PEPTIDES, AND METHODS FOR TREATING SAID INDIVIDUALS (2003-12-30),

2. 6284476 - Method of identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen/tyrosinase derived peptides, and methods for treating said individuals (2001-09-04),

3. 6201111 - Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursors (2001-03-13),

4. 6096520 - Brain glycogen phosphorylase cancer antigen (2000-08-01),

5. 6001975 - Precursor processed to at least one tumor rejection antigen presented by (1999-12-14),

6. 5958711 - Methods for determining expression of NAG tumor rejection antigen (1999-09-28),

7. 5886145 - Isolated nucleic acid molecules, peptides which form complexes with MHC (1999-03-23),

8. 5856091 - Isolated nucleic acid sequence coding for a tumor rejection antigen (1999-01-05),

9. 5854203 - Tumor rejection antigen precursor processed to at least one tumor (1998-12-29),

10. 5843688 - Isolated tyrosinase derived peptides and uses thereof (1998-12-01),

11. 5843687 - Isolated, tyrosinase derived peptides and uses thereof (1998-12-01),

12. 5837476 - Methods for determining disorders by assaying for a non-tyrosinase, (1998-11-17),

13. 5821122 - Isolated nucleic acid molecules, peptides which form complexes with MHC (1998-10-13),

14. 5747271 - Method for identifying individuals suffering from a cellular abnormality (1998-05-05),

15. 5744316 - Isolated, tyrosinase derived peptides and uses thereof (1998-04-28),

Title: Vincent Brichard: Innovator in Cellular Abnormality Research

Introduction: Vincent Brichard is a prominent inventor based in Brussels, Belgium, with a remarkable portfolio of 19 patents. His groundbreaking work primarily revolves around the identification and treatment of individuals suffering from cellular abnormalities, particularly in relation to complex human leukocyte antigen (HLA) and tyrosinase-derived peptides.

Latest Patents: Among his notable patents, Vincent's latest inventions include a method for identifying individuals suffering from cellular abnormalities wherein some of their abnormal cells present complexes of human leukocyte antigen/tyrosinase-derived peptides. This invention has significant therapeutic and diagnostic implications, offering potential solutions for affected individuals. The focus on complexes of HLA molecules on abnormal cells underscores his dedication to advancing medical science and improving patient outcomes.

Career Highlights: Throughout his career, Vincent Brichard has contributed to various prestigious research organizations. He has been affiliated with the Ludwig Institute for Cancer Research Limited and the Institut National de la Santé et de la Recherche Médicale, where his work has helped shape the landscape of cancer research and cellular biology.

Collaborations: Vincent has collaborated with esteemed colleagues such as Thierry R Boon-Falleur and Aline van Pel. These partnerships have been instrumental in fostering innovation and driving forward significant advancements in the field of medical research.

Conclusion: Vincent Brichard's innovative contributions to the understanding of cellular abnormalities position him as a pivotal figure in the realm of medical advancements. His patents and collaborations exemplify the impact of dedicated research and the importance of continuous innovation in improving healthcare outcomes for individuals affected by serious medical conditions.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com